Following a period of experimentation, life sciences is entering a pivotal new phase in AI adoption. The industry is shifting away from hype-driven pilots and toward proven, value-led applications that improve how therapies are developed, launched, and delivered to patients. What’s becoming clear is that the true differentiator won’t just be more algorithms, it will be how companies reimagine their people, processes, and data to unlock AI’s potential.